-transparent.png){kind=logo}
O6-Benzylguanine effectively inactivates the DNA repair protein, O6-alkylguanine-DNA alkyltransferase, leading to an increase in the therapeutic index of 1,3-bis(2-chloroethyl)-1-nitrosourea in nude mouse xenograft studies. To investigate the fate of this inactivator in mammalian systems, we examined its biodistribution and metabolism following i.p. administration of 8-[3H]-O6-benzylguanine to male Sprague-Dawley rats and BALB/c mice. Following administration to rats, there were significantly higher levels of radioactivity in liver than in lung, spleen, kidney, small intestine, and esophagus for up to 24 h. Major urinary metabolites were identified as O6-benzyl-7,8-dihydro-8-oxoguanine, N2-acetyl-O6-benzylguanine, and N2-acetyl-O6-benzyl-7,8-dihydro-8-oxoguanine. Debenzylated metabolites included guanine, 7,8-dihydro-8-oxoguanine, and N2-acetylguanine. In contrast to rat metabolism, acetylated derivatives were not found in mouse urine. However, O6-benzyl-7,8-dihydro-8-oxoguanine was a major metabolite in the mouse. O6-Benzyl-7,8-dihydro-8-oxoguanine was a very effective O6-alkylguanine-DNA alkyltransferase inactivator and exhibited a 50% effective dose in HT29 cell extracts of 0.3 microM compared to 0.2 microM for O6-benzylguanine. The O6-alkylguanine-DNA alkyltransferase depleting activity of N2-acetyl-O6-benzylguanine and N2-acetyl-O6-benzyl-7,8-dihydro-8-oxoguanine were, respectively, 120- and 325-fold lower than O6-benzylguanine in HT29 cell-free extracts.
M E Dolan, and
M Y Chae, and
A E Pegg, and
J H Mullen, and
H S Friedman, and
R C Moschel
January 2004,
Neuro-oncology,
M E Dolan, and
M Y Chae, and
A E Pegg, and
J H Mullen, and
H S Friedman, and
R C Moschel
November 1993,
Biochemistry,
M E Dolan, and
M Y Chae, and
A E Pegg, and
J H Mullen, and
H S Friedman, and
R C Moschel
July 2000,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
M E Dolan, and
M Y Chae, and
A E Pegg, and
J H Mullen, and
H S Friedman, and
R C Moschel
May 1998,
The Journal of biological chemistry,
M E Dolan, and
M Y Chae, and
A E Pegg, and
J H Mullen, and
H S Friedman, and
R C Moschel
December 1994,
Cancer research,
M E Dolan, and
M Y Chae, and
A E Pegg, and
J H Mullen, and
H S Friedman, and
R C Moschel
January 2001,
Cancer chemotherapy and pharmacology,
M E Dolan, and
M Y Chae, and
A E Pegg, and
J H Mullen, and
H S Friedman, and
R C Moschel
March 1999,
Clinical cancer research : an official journal of the American Association for Cancer Research,
M E Dolan, and
M Y Chae, and
A E Pegg, and
J H Mullen, and
H S Friedman, and
R C Moschel
May 1998,
Cancer research,
M E Dolan, and
M Y Chae, and
A E Pegg, and
J H Mullen, and
H S Friedman, and
R C Moschel
May 1997,
Biochemical pharmacology,
M E Dolan, and
M Y Chae, and
A E Pegg, and
J H Mullen, and
H S Friedman, and
R C Moschel
January 2000,
Methods in molecular biology (Clifton, N.J.),
